Santhera Pharmaceuticals Holding AG
SANN
Classement en actions
#16119
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Prix de l'action
$17.84
Capitalisation boursière
$272.97M
Changement (1 jour)
-6.69%
Changement (1 an)
39.04%
Pays
CH
Échange Santhera Pharmaceuticals Holding AG (SANN)
Catégorie
Healthcare
Ratio P/S pour Santhera Pharmaceuticals Holding AG (SANN)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Santhera Pharmaceuticals Holding AG, le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Santhera Pharmaceuticals Holding AG de 2026 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
